Clinical trial
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial…
NCT00022659 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00022659 |
|---|---|
| Title | Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
| Official title | A Phase II Evaluation of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC #704865) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer |
| Intervention type | Biological, Other |
| Interventions | bevacizumab, laboratory biomarker analysis |
| Enrollment | 64 |
| Start date | Apr 1, 2002 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 24, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: